A deep analysis of the EU JCA process and how sponsors should prepare for integration of Regulatory and HTA dossiers and timeline alignment

Sponsors should treat the EU Joint Clinical Assessment (JCA) as a tightly timeboxed, PICO-driven, comparative clinical evidence exercise that starts off the back of the EMA marketing authorisation (MA) workflow and design their internal processes so the HTA evidence package is ready in parallel with (and not after) the regulatory dossier. The practical implication is that sponsors’ success in JCA will depend on having the right evidence in the right comparative structure (PICO, comparators, endpoints) with traceability and uncertainty handled in a way that fits how HTA bodies will interpret the dossier.

The core features sponsors should plan around (based on current publicly described JCA implementation) are:

• JCA is a scientific analysis of relative effects of the health technology on health outcomes, including “the degree of certainty … taking into account strengths and limitations of the available evidence.”
• For medicines, once sponsors submit the EMA marketing authorisation application, sponsors must simultaneously submit to the HTA secretariat the summary of product characteristics (SPC) and the clinical overview (CO) from the marketing authorisation application. This is used to establish the scope.
• The JCA dossier build window is compressed: after the required PICOs are decided, the sponsor has roughly three months to submit the JCA dossier.

How sponsors should prepare to maximise chances of a successful outcome

1. Build an HTA-ready evidence map immediately (do not wait for the final EMA package)

Starting point: because JCA scope is PICO-based and is established using information submitted at the time of the MA submission, sponsors should pre-build a PICO-to-evidence mapping as part of sponsors regulatory lifecycle (not at the end).

Practical execution: maintain a live matrix linking each PICO element (population, intervention, comparator(s), outcomes) to trial reports, key subgroup/exposure evidence, ML/BRIDGE analyses (if any), and safety/benefit/risk relevance. Then sponsors can repackage without redoing analysis.

• Get PICO right early, and align it with what sponsors can support credibly

Since the manufacturer must prepare the JCA dossier after the end of the PICO survey and must acknowledge all PICOs identified through scoping, sponsors should assume scope decisions may incorporate multiple PICOs. Also, identify sub-group outcomes sponsors need to be ready to defend.

A recurring risk in early HTA dossier practice is overproduction of endpoints/subgroups without downstream consideration. One analysis of dossier template effects reported that any change increased workload substantially, and that many adverse-event analyses and subgroup categories were not even considered by benefit assessment bodies.

Implication for sponsors: don’t indiscriminately include every possible analysis. Include what is methodologically defensible and directly supports the PICOs/decision points expected to be central.

• Comparators and outcomes must match clinical practice replacement logic, not everything in the label

Recommendations from EU HTA-oriented literature emphasise limiting economic model/comparator breadth to those therapies most likely to be replaced in clinical practice, rather than all available therapies.

Even though that specific text is about economic modelling relevance, the underlying message transfers well: comparators/outcomes in the JCA dossier need to be chosen for decisional relevance to the PICO.

• Treat uncertainty and relative effect as first-class deliverables

Because the JCA is explicitly about relative effects and degree of certainty, sponsors should design evidence synthesis to produce clear statements on confidence/limitations (study design limits, indirectness, missing data, multiplicity, assay heterogeneity, etc.) mapped to the PICO question structure.

Operationally, that means internal review checklist should score:

(a) whether each limitation is traceable to a PICO conclusion, and

(b) whether uncertainty is quantified/qualified consistently across endpoints and subgroups.

• Start dossier authoring in “regulatory-parallel” mode, using the JCA dossier structure

The European Commission’s JCA dossier guidance/template for medicinal products exists and is designed to standardise what sponsors must provide.

Because the submission is expected to happen soon after EMA validation milestones and PICO decisions, sponsors should use the template structure from day one (section ownership, evidence insertion rules, consistent citation/numbering, and version control), rather than translating a completed regulatory clinical overview at the end.

How the HTA dossier should be aligned with the regulatory dossier (consistency and timing)

1. Use the required simultaneous submission as anchor

For relevant medicinal products with EMA marketing authorisation applications after 12 Jan 2025, the process requires simultaneous submission of:

• summary of product characteristics and
• clinical overview of the marketing authorisation application to the HTA secretariat which is used to set scope.

Therefore, the regulatory clinical overview must be written so it can serve as the factual backbone for JCA scope establishment (terminology, comparator descriptions, key endpoints, and evidence hierarchy).

• Ensure both dossiers share the same source-of-truth for evidence, but allow HTA-specific framing

Alignment goal: consistency of evidence, population definitions, comparator naming, endpoint definitions, and cut dates (data freeze dates). 

HTA-specific framing: even if the evidence is the same, JCA will reorganise it around PICOs and comparative effects/uncertainty. Keep a translation layer between regulatory wording and PICO wording, but don’t let that layer introduce contradictions.

• Time internal evidence cutoffs around the JCA PICO decision and ~3-month submission expectation

After PICO survey/consolidation, the sponsor has about three months to submit the JCA dossier (per the described timeline logic).

To hit that, sponsors need regulatory-to-HTA synchronisation on: final analyses, subgroup definitions sponsors want to stand behind, and any re-analysis need for comparability/indirectness.

What sponsors can reasonably predict about future applications (given what’s known so far)

JCA will reward sponsors who:

(a) can rapidly convert regulatory clinical evidence into PICO-scoped comparative arguments and

(b) can clearly articulate certainty/limitations linked to the JCA’s relative-effect framing.

Sponsors will likely continue to face a workload trap if they over-expand endpoints/subgroups without ensuring those analyses are decision-relevant; observed template changes have historically increased dossier analytical volume, while a substantial fraction of analyses may not be taken up in assessment conclusions.

Because JCA is meant to run in parallel with MA review and ends with endorsement aligned to marketing authorisation milestones, delays in reconciling evidence for PICO framing are likely to be penalised more than minor wording differences. Prioritise speed-to-traceable-evidence.

Gaps in the JCA process identified so far

The main gaps are not necessarily failures of the JCA framework; most are implementation gaps revealed by the first wave of work. Importantly, HTACG’s formal publications tend to describe these as areas requiring clarification, process learning or further development, whereas some of the sharper criticisms come from sponsors, patients, clinicians and independent analyses.

1. PICO scoping remains insufficiently predictable

The largest gap is the limited transparency and predictability of how Member State needs are converted into the final PICO scope.

The current process allows Member States to propose different populations, comparators, subgroups and outcomes, which are then consolidated into a smaller set of PICOs. However, sponsors have limited visibility of:

• How the initial PICO proposals are generated.
• Why one Member State proposal is retained and another is rejected.
• How conflicting national standards of care are reconciled.
• When differences justify separate PICOs rather than a consolidated PICO.
• How the likely number and complexity of PICOs will affect the dossier burden.

HTACG’s scoping guidance provides the procedural framework, but it does not fully disclose the decision rules used to create or consolidate PICOs. The resulting uncertainty is particularly important because the PICO scope determines the evidence that the sponsor must provide, while the sponsor has very limited ability to reshape the scope after it is finalised. Stakeholder feedback has specifically identified the lack of transparency in initial PICO formulation and consolidation as a problem.

This is more than a procedural inconvenience. A PICO can request a population or comparator that does not correspond to the pivotal trial, the EMA indication, or a single European standard of care. The sponsor may then be required to address an evidence question that was not part of the clinical development plan. HTACG’s own methodological Q&A confirms that where no valid direct or indirect comparison exists for a PICO, this is an evidence gap.

Likely consequence

Future JCAs will probably continue to produce a tension between:

• A small number of broad PICOs that are efficient but may be clinically heterogeneous.
• A larger number of narrow PICOs that are more locally relevant but create substantial analytical and interpretive burden.

Sponsors should therefore assume that the number of PICOs—and not merely the size of the underlying clinical programme—will be a principal driver of JCA complexity.

• Comparator selection is not yet fully operationalised

Comparator choice is a recurring weakness, particularly where European treatment pathways differ or where a PICO uses a blended comparator such as individualised treatment.

A conventional randomised trial may compare the new medicine with one control treatment, whereas the PICO may ask about:

• Several alternative treatments.
• A treatment class.
• Physician’s choice.

Individualised treatment comprising multiple regimens.

• A comparator that is standard in some Member States but not others.
• A treatment used in clinical practice but not included in the pivotal study.

The practical gap is that the process may identify a comparator that is clinically relevant at national level without providing a sufficiently clear or consistently applicable method for estimating relative effects against it. Recent analysis has highlighted the disconnect between possible PICO requests including blended comparators and the evidence-synthesis methods available to sponsors.

This is especially problematic for oncology, rare diseases and ATMPs, where:

• Treatment sequences differ across countries.
• Standard care changes rapidly.
• Trials often use a single control.
• The relevant comparator may be a combination of treatments.
• Some comparator regimens have little head-to-head evidence.

Likely consequence

A sponsor can submit a methodologically correct analysis and still receive a weak JCA conclusion because the requested comparator is not adequately represented in the evidence base. This is an evidence-generation problem, not simply a dossier-writing problem.

• The framework is strongest for RCTs and weaker for immature or non-randomised evidence

The JCA methodology is relatively comfortable with a well-designed randomised controlled trial that directly compares the intervention with a clearly specified comparator. It is less settled when the evidence relies on:

• Single-arm trials.
• External controls.
• Indirect treatment comparisons.
• Network meta-analysis.
• Real-world evidence.
• Small, non-comparative ATMP studies.
• Surrogate outcomes.
• Immature overall-survival data.
• Long-term durability assumptions.
• Cross-trial comparisons with materially different populations or follow-up.

HTACG’s Q&A is clear that an indirect comparison can be assessed, but the methodology and its outcome must be described in the JCA report.  That does not eliminate the underlying limitation: an indirect comparison may be necessary because the evidence base does not contain a direct comparison, but it can still have serious transitivity, consistency and precision problems.

The gap is therefore not simply whether indirect evidence is allowed. It is whether sponsors can anticipate:

• Which methods will be considered acceptable.
• Which effect modifiers must be adjusted for.
• What level of methodological detail will be expected.
• How much uncertainty will be tolerated.
• How immature evidence should be presented without overstating conclusions.

This matters particularly for ATMPs and rare conditions, which frequently involve small populations, limited follow-up and ethical constraints on randomised trials. Independent reviews have identified these as structural challenges for JCA implementation.

• There is no complete solution for cross-country clinical heterogeneity

The JCA is intended to produce a common clinical evidence assessment, but the clinical context in which a medicine is used is not uniform across Europe.

Differences may exist in:

• Treatment sequencing.
• Eligibility for subsequent lines.
• Use of maintenance therapy.
• Diagnostic testing.
• Background supportive care.
• Access to comparators.
• Definition of standard of care.
• Management after disease progression.
• Use of transplantation, radiotherapy or combination treatment.
• Patient monitoring and treatment discontinuation.

A single European PICO may therefore conceal important national differences. Conversely, accommodating every difference may lead to a large, fragmented assessment that is difficult for either assessors or national agencies to use.

The first JCA reports show that contextual material such as treatment pathways and expert input is included, but the report remains a clinical-effects assessment rather than a national value assessment. The official JCA factsheet confirms that JCAs cover clinical domains only and do not make reimbursement conclusions; national authorities retain responsibility for national HTA and reimbursement decisions.

Likely consequence

The JCA may reduce duplication without completely eliminating national evidence requirements. A national agency cannot repeat the clinical assessment in the same way, but it may still need to interpret the JCA in its own treatment pathway and supplement it with local information. This creates a residual risk of divergent national submissions and analyses.

• The assessment methodology is still developing through live cases

HTACG has adopted guidance and templates, but the first assessments are also functioning as practical tests of the system. The 2025 HTACG work included assessment activity, assessor support, learning from assessments, a JCA report template and work on open issues from a gap analysis.

The implication is that the written framework is not yet the same as a mature, fully standardised operating model. Important elements are being clarified through:

• PICO simulation exercises.
• Early assessments.
• Questions and answers.
• Assessor experience.
• Stakeholder feedback.
• Revisions to templates and procedural materials.

This creates a moving-target problem for sponsors. Guidance available at the start of a programme may not fully predict how a later JCA team handles data cuts, subgroup analyses, indirect comparisons, missing data or factual corrections.

The first published lurbinectedin JCA illustrates the operational reality. The dossier went through multiple versions, including responses to requests for additional information, and the assessors excluded some submitted results because of methodological flaws or inappropriate analysis methods.  The report also records that incorrect subgroup analyses were identified during the factual accuracy process, while the corrected results were not incorporated into the main JCA report because the correction occurred at that stage.

This does not necessarily indicate an error by HTACG. It does, however, identify a real process gap: the factual accuracy check is relatively late, and late corrections may not fully repair an analytical or presentation problem in the final report.

• Timelines and capacity are a major implementation risk

The JCA must be completed within a timetable linked to the EMA marketing authorisation process. At the same time, HTACG must identify assessors, co-assessors, experts, patients and clinicians; conduct the assessment; manage sponsor questions; perform factual checks; finalise the report; and obtain endorsement.

HTACG itself has recognised the need to balance detailed information requirements with timely expert identification, improve communication and outreach, and provide clearer explanatory materials. These were recorded as lessons learned in the 2025 stakeholder-related work.

The capacity challenge will become more significant as the scope expands:

• From 2025, new oncology medicines and ATMPs are in scope.
• Orphan medicines are added in the next phase.
• The scope later expands further under the stepwise implementation model.

The risk is not only assessor workload. Sponsors likely face several compressed activities at once:

• EMA responses and final regulatory analyses.
• PICO clarification and scope review.
• JCA dossier preparation.
• Additional information requests.
• Factual accuracy review.
• National HTA submissions.
• Pricing and reimbursement preparation.

Likely consequence

The process may become more vulnerable to:

• Delayed expert recruitment.
• Reduced time for methodological debate.
• Repeated requests for information.
• Inconsistent handling of similar analytical issues.
• Greater reliance on sponsor-provided analyses.
• Less opportunity to correct errors before endorsement.
• Evidence quality control and data-cut management need further maturation

The first JCA experience shows that apparently small technical choices can affect whether evidence is included or how it is interpreted. Examples include:

• Selecting the relevant data cut.
• Reconciling multiple data cuts.
• Defining the analysis population.
• Handling different follow-up durations.
• Choosing risk ratios, risk differences or odds ratios for safety.
• Handling missing patient-reported outcome data.
• Defining response, duration of response and progression.
• Conducting subgroup analyses.
• Separating prespecified analyses from exploratory analyses.

In the lurbinectedin report, certain safety results were not used because the later data cut and the differing observation durations made the submitted effect measures potentially less valid.  The report also identified limitations in outcome definitions and analysis methods.

The gap is that sponsors do not yet have a fully predictable “JCA standard” for all these decisions. The regulatory dossier may contain analyses that are acceptable for benefit-risk review but not sufficiently aligned with the comparative-effectiveness questions posed by JCA.

• Stakeholder involvement is established but still limited in influence and timing

Patients and clinical experts are involved in the assessment scope and in review of draft JCA and summary reports. The lurbinectedin report, for example, documents written input from a carer and a clinical expert at both stages.

However, the main gap is not the absence of stakeholder involvement; it is the practical influence and timing of that involvement. Stakeholder input may help clarify:

• The clinically meaningful population.
• Treatment sequencing.
• Relevant outcomes.
• Burden of disease.
• Acceptability of adverse effects.
• The realism of comparator choices.

But stakeholders generally do not determine the final PICO or the analytical method. Their input may arrive after the initial PICO proposals have already been formulated, and they may have limited ability to challenge the technical consequences of a consolidated scope.

This is particularly important where the technically neat PICO is not the clinically most meaningful. For example, when overall survival is immature but symptoms, function or treatment burden are important to patients.

• Confidentiality and publication rules create a practical tension

The JCA is intended to support transparency and reuse by national HTA bodies. HTACG has also emphasised that information already in the public domain, clinical-trial methodologies, trial results, clinical data and evidence-synthesis approaches should not generally be treated as commercially confidential.

That creates a predictable tension for sponsors:

• The JCA dossier must contain enough detail to be reproducible and useful.
• Public disclosure may expose analyses, assumptions and weaknesses.
• The factual accuracy process does not provide a full opportunity to rewrite the assessment.
• Confidentiality claims may be rejected where data are considered clinical evidence rather than commercially sensitive information.

The gap is therefore a need for clearer, consistently applied rules on:

• What may be redacted.
• How confidential supporting data are referenced.
• How unpublished analyses are presented.
• How sponsor corrections are handled after factual review.
• How the public report and national dossier interact.

1. The JCA-to-national-HTA handoff is not yet fully resolved

A JCA report is not a pan-European reimbursement decision. National authorities must give it due consideration, but they remain responsible for national HTA and reimbursement. The JCA factsheet states that national authorities must annex both the developer’s dossier and the published JCA report to their national HTA documentation.

That creates a structural gap between:

• The EU PICO and the national decision problem.
• The JCA clinical assessment and national economic evaluation.
• The JCA data cut and the national submission data cut.
• The JCA endpoint interpretation and national clinical-value frameworks.
• The common JCA dossier and country-specific submission requirements.

The EU-level assessment may conclude that relative effects are uncertain, while a national agency may need to decide whether the uncertainty is acceptable for a particular reimbursement pathway. The JCA does not itself provide the value judgment, cost-effectiveness conclusion, budget impact or managed-entry recommendation.

What this means for sponsors

The most important practical conclusion is that the JCA should not be treated as a single replacement for all national HTA work. It should be treated as a common clinical evidence layer that must be deliberately linked to national decision problems.

Sponsors should prepare for five recurring risks:

Overall assessment

The central gap is predictability. HTACG has created a functioning legal, procedural and methodological foundation, and the first reports demonstrate that assessments can be completed and endorsed. But the early experience still shows uncertainty about how scope is set, how complex comparator questions are handled, how non-RCT evidence is judged, how late corrections are treated, and how the EU report will translate into national decision-making.

For future sponsors, the safest assumption is that the JCA will be most successful when the development programme is designed around three parallel requirements:

1. Regulatory evidence sufficient to establish benefit-risk and obtain the MA.
2. Comparative evidence that directly answers plausible European PICOs.
3. A transparent uncertainty framework that allows national HTA bodies to reuse the JCA without reconstructing the clinical analysis.

The first requirement is familiar to sponsors. The second and third are where the current HTACG experience indicates the greatest remaining gaps.

www.pharma-design.co.uk